Alliance of Community Health Plans (ACHP)’s Post

⚡ ⚖ 💊 BREAKING NEWS for SPC enthusiasts - Newron's appeal to the UK Court of Appeal has been dismissed and (pending any further appeal) their SPC application based on safinamide (Xadago) is refused. For patentees/SPC applicants, it will be disappointing to see another category - now 'add on therapies' - added to the growing list of patentable inventions that do not qualify for SPC protection. Otherwise, in upholding both of the preceding decisions, the UK court has confirmed a willingness to adopt a strict approach when assessing the "product" of an SPC. This endorsement, especially of the CJEU decision in Santen (and not Neurim), is an interesting (and perhaps inescapably negative) context for those hoping that the UK Court of Appeal might depart from CJEU precedent. This will of course be tested in another upcoming appeal that seeks to turn back time to a Neurim-style teleological approach. #SPCs #patentlaw #pharmaceuticals

To support their 14-page report titled "Big Pharma’s Business Model: Corporate Greed", the Senate HELP Committee used our Drug Patent Book to get a full look at the scale of Johnson & Johnson, Merck, and Bristol Myers Squibb’s patenting tactics. Putting together The Drug Patent Book was a massive undertaking, requiring our team of scientists and patent/IP attorneys to spend hundreds of hours digging far beyond the limited patent information that is publicly available in order to identify as many patents as we could find that cover a specific drug. Chances are we probably missed some patents so the numbers could well be higher. But this is exactly why we did it. This comprehensive, publicly accessible patent data wasn’t available before. In fact, the number of patents drugmakers filed on a drug product was a closely guarded secret. I-MAK’s hope was that with a more in-depth understanding of just how serious the overpatenting problem is, policymakers, regulators, and the public would be able to draft and call for evidence-based solutions and not faith-based ones. This report and today's Senate hearing are two encouraging steps towards realizing that goal.  You can look through The Drug Patent Book yourself at https://lnkd.in/g6vcTGNc.

FDA Rethinking Automatic 30-Month Stay in Patent Thickets After Endo Sues: A new chapter emerged this week in the contentious issue of patent thickets, a web of overlapping patents filed on a single existing product to create barriers to competition and extend effective patent life. #fda #financial #lifesciences

Read our POLITICO Focus Brief to learn why reforming the U.S. patent system will improve competition and reduce prescription drug costs. In the brief, we call on policymakers to introduce evidence-based policies that will address America’s drug patent problem at its root. 📑 https://politi.co/3UiJZIp

Are drugmakers abusing the patent system to reduce competition? And, if so, will the recent coordination between the PTO and FDA help to protect against such abuse? Recent research letters published in JAMA suggest that the answers are yes and yes. Read more below. #DrugCosts #PatentAbuse #Competition #PTO #FDA

It was an honor to speak on the importance of patent reform, specifically our support at Generation Patient of Senator Welch, Klobuchar, and Braun's bipartisan legislation to address patent thickets on Capitol Hill yesterday. Patent thickets are when companies file a web of additional patents beyond the primary patent, which prevents competition, discourages innovation, and keeps drug prices high. This legislation is a crucial start to protecting innovation while ensuring timely access to biosimilars and generics. You can learn more about the legislation here: https://lnkd.in/ga4vmfvu ... As young adult patients, our ability to thrive into adulthood depends on whether we can afford life-saving medicines. This legislation addressing patent thickets is crucial to ensuring timely access to biosimilars and generics. All patients should have access to medicines, not just those who can afford them. We at Generation Patient are proud to endorse this legislation, impacting the current generation and the next generation of patients.

Patent Invalidity case: Bayer Vs Sandoz Bayer's patent Xarelto; the best-selling blood thinner is held invalid, by the London's High Court. Bayer’s European patent over once-daily rivaroxaban, with a brand name of ‘Xarelto’, has now been declared invalid following legal challenges brought by Sandoz and other rival manufacturers. Bayer's attempts to replace Xarelto were thrown into doubt last year when it aborted a large late-stage trial testing a new anti-clotting drug due to lack of efficacy. Judge Richard Hacon said Bayer's patent was invalid because of the lack of an "inventive step" in developing the drug. Read more @ https://lnkd.in/dFqpE6nf #patent #patentvalidity #patentinvalidity #intellectualproperty #ipnews

Thoughts on this? >> NJ federal judge rules Teva inhaler patents are 'improperly listed' in Orange Book >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharma #productmarketing #pharmaceutical

Wrap up your week with our DrugPatentWatch Week in Review. From significant patent expirations to new drug launches, we bring you the most important updates. Make sure your decisions are backed by the latest information. #PharmaWeekly #PatentNews #DrugLaunches #DrugPatentWatch

Thoughts on this? >> Federal judge rules FDA can move forward with potential approval of Liquidia's version of Tyvaso >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #healthcare #biotech #productmarketing